// App-Quantinova.ai

9506 : CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma.

Researchers

Presenter

  • Jedd D. Wolchok

Principal Investigators

  • Rene Gonzalez

  • Jean-Jacques Grob

  • Piotr Rutkowski

  • Christopher D. Lao

  • Charles Lance Cowey

  • Dirk Schadendorf

  • John Wagstaff

  • Reinhard Dummer

  • Pier Francesco Ferrucci

  • Michael Smylie

  • Marcus O. Butler

  • Andrew Graham Hill

  • Ivan Marquez-Rodas

  • John B. A. G. Haanen

  • Tuba Bas

  • Wim van Dijck

  • F. Stephen Hodi

  • James Larkin

Medical Centers

  • Medical Oncology, Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College, New York, NY, Oncology Institute of Veneto IRCCS, Padua, Italy

  • University of Colorado Cancer Center, Denver, CO, Aix-Marseille University, APHM, Hôpital Timone, Marseille, France

  • Maria Sklodowska-Curie Institute of Oncology, Warsaw, Poland

  • Michigan Medicine, Rogel Cancer Center, University of Michigan, Ann Arbor, MI, Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX

  • Department of Dermatology, University of Essen, Essen, and German Cancer Consortium, Heidelberg, Germany

  • College of Medicine, Swansea University, Swansea, United Kingdom

  • Skin Cancer Center, University Hospital of Zürich, Zürich, Switzerland

  • European Institute of Oncology, Milan, Italy

  • Cross Cancer Institute, Edmonton, AB, Canada

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Tasman Oncology Research, Southport, Australia

  • Medical Oncology, General University Hospital Gregorio Marañón & CIBERONC, Madrid, Spain

  • Netherlands Cancer Institute (NKI), Amsterdam, Netherlands

  • Bristol Myers Squibb, Princeton, NJ, Bristol-Myers Squibb, Princeton, NJ, Dana-Farber Cancer Institute, Boston, MA

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

Locations

  • Italy

  • France

  • Poland

  • Germany

  • United Kingdom

  • Switzerland

  • Canada

  • Australia

  • Spain

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Melanoma

Biomarkers

  • B-Raf proto-oncogene, serine/threonine kinase

  • Programmed death-ligand 1

Drug/Treatment

  • Nivolumab

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • III

Study Id's

  • NCT01844505

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved